A dose-ranging study of phenylpropanolamine on nasal airflow.

Abstract

A double-blind randomized placebo-controlled study comparing the effect of 2-dose levels of phenylpropanolamine (PPA) for acute rhinitis was performed in 180 outpatients. PPA was given in a fixed dose combination with paracetamol, chlorpheniramine and vitamin C. Two doses of each drug were given with a 4-h interval. Based on objective evaluation of nasal airflow using a Connell rhinometer, it was shown that PPA 25 mg was significantly more effective than the active placebo and PPA 15 mg. The decongestant effect of PPA 25 mg was markedly seen after 1 h, becoming maximal after 1.5 h, and was maintained for 2 h, after which the effect decreased until just before the second dose was given. The second dose gave a similar result as the first dose. PPA 15 mg was less effective and of shorter duration than the 25 mg dose, but gave sufficient improvement of nasal congestion.

• Authors: I Darmansjah, H T Akib, A Setiawati, A Muchtar, N Rifki
• Journal: International journal of clinical pharmacology, therapy, and toxicology (Int J Clin Pharmacol Ther Toxicol) Vol. 28 Issue 7 Pg. 282-5 (Jul 1990) ISSN: 0174-4879 [Print] Germany
• PMID: 2387651 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Phenylpropanolamine

Topics

• Dose-Response Relationship, Drug
• Double-Blind Method
• Female
• Humans
• Male
• Monitoring, Physiologic
• Nose
• Phenylpropanolamine (administration & dosage, therapeutic use)
• Pulmonary Ventilation (drug effects)
• Random Allocation
• Rhinitis (drug therapy)